GENZYME Presents at 7th Annual Life Science CEO Forum, Jan-26-2016 10:30 AM
Jan 22 16
GENZYME Presents at 7th Annual Life Science CEO Forum, Jan-26-2016 10:30 AM. Venue: Westin Buckhead Hotel, Atlanta GA, United States. Speakers: Stephanie S. Okey, Head of North America, Rare Diseases & Senior Vice President, US General Manager.
Genzyme Announces Positive New Five-Year Investigational Data from the Extension Study of Lemtrada® (alemtuzumab)
Oct 8 15
Genzyme announced positive new five-year investigational data from the extension study of Lemtrada® (alemtuzumab) for patients with relapsing remitting multiple sclerosis (RRMS). These results will be presented on October 9, 2015 at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain. In RRMS patients treated with Lemtrada in the Phase III pivotal studies, the effects described below observed in the two-year trials were maintained through three additional years in the extension study (years three, four and five). After the initial two courses of treatment in the pivotal studies, which were given at month zero and at month 12, 68% of Lemtrada patients from CARE-MS I and 60% from CARE-MS II did not receive additional Lemtrada treatment during the following four years, through month 60. The low annualized relapse rates observed in patients who received Lemtrada in CARE-MS I (0.18) and CARE-MS II (0.27) were maintained from year three (0.19 and 0.22) to year five (0.15 and 0.18). Through year five, 80% and 76% of patients who received Lemtrada in CARE-MS I and CARE-MS II, respectively, did not experience worsening of disability progression confirmed over six months as measured by the Expanded Disability Status Scale (EDSS). Through year five, 33% and 43% of patients who had some disability before receiving Lemtrada in CARE-MS I and CARE-MS II, respectively, had improvement in EDSS score confirmed over at least six months as compared with pre-treatment baseline. Through year five, patients who received Lemtrada in CARE-MS I and II experienced a slowing of brain atrophy as measured by brain parenchymal fraction on magnetic resonance imaging (MRI). In years three, four and five, the median yearly brain volume loss was -0.20% or less, which was lower than what was observed during the two-year pivotal studies. Through year five, the incidence of most adverse events during the extension study was comparable or reduced compared with the pivotal studies. The frequency of thyroid adverse events was high in year three and declined thereafter. The Phase III trials of Lemtrada were randomized, rater-blinded, two-year pivotal studies comparing treatment with Lemtrada to high-dose subcutaneous interferon beta-1a (Rebif®) in patients with RRMS who had active disease and were either new to treatment (CARE-MS I) or who had an inadequate response to another therapy (CARE-MS II).
Genzyme Presents at AusBiotech National Conference 2015, Oct-09-2015 11:30 AM
Oct 5 15
Genzyme Presents at AusBiotech National Conference 2015, Oct-09-2015 11:30 AM. Venue: Victoria, Australia. Speakers: Andre Turenne, Managing Director.